Platelet activation in coronary artery disease: Intracardiac vs peripheral venous levels and the effects of angioplasty

Chest

Volumn 132, Issue 5, 2007, Pages 1532-1539

  Jaumdally, Rumi J ^a   Varma, Chetan ^a   Blann, Andrew D ^a   MacFadyen, Robert J ^a   Lip, Gregory Y H ^a,b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Cardiology; Platelets; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; AORTA ROOT; ARTICLE; ATHEROMA; CORONARY ARTERY DISEASE; CORONARY SINUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL VEIN; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME;

EID: 36348960065     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0389     Document Type: Article

References (45)

1. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45:1157-1164
2. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339:436-443
3. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med 1998; 339:415]. N Engl J Med 1998; 38:1488-1497
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330:956-961
5. Schuhlen H, Kastrati A, Mehilli J, et al. Abciximab and angiographic restenosis after coronary stent placement: analysis of the angiographic substudy of ISAR-REACT; a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Am Heart J 2006; 151:1248-1254
6. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531-1538
7. Neuhaus KL, Zeymer U. Prevention and management of thrombotic complications during coronary interventions: combination therapy with antithrombins, anti-platelets, and/or thrombolytics; risks and benefits. Eur Heart J 1995; 16:63-67
8. Mayadas TN, Johnson RC, Rayburn H, et al. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 1993; 74:541-554
9. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24:2166-2179
10. Conway DS, Pearce LA, Chin BS, et al. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106:1962-1967
11. Nadar SK, Caine GJ, Blann AD, et al. Platelet adhesion in hypertension: application of a novel assay of platelet adhesion. Ann Med 2005; 37:55-60
12. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004; 109:2524-2528
13. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22:1668-1673
14. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporarily limited by coexpressed CD40. Blood 2001; 98:1047-1054
15. Jagroop IA, Clatworthy I, Lewin J, et al. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11:28-32
16. Threatte GA. Usefulness of the mean platelet volume. Clin Lab Med 1993; 13:937-950
17. Pizzulli L, Yang A, Martin JF, et al. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998; 19:80-84
18. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7:157-161
19. Kini AS, Lee PC, Mitre CA, et al. Prediction of outcome after percutaneous coronary intervention for the acute coronary syndrome. Am J Med 2003; 115:708-714
20. Huczek Z, Kochman J, Filipiak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005 19; 46:284-290
21. Norgaz T, Hobikoglu G, Aksu H, et al. The relationship between preprocedural platelet size and subsequent in-stent restenosis. Acta Cardiol 2004; 59:391-395
22. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21:1406-1432
23. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease: report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51(suppl):5-40
24. Kabbani SS, Watkins MW, Holoch PA, et al. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. J Thromb Thrombolysis 2001; 12: 171-176
25. Inoue T, Hoshi K, Fujito T, et al. Early detection of platelet activation after coronary angioplasty. Coron Artery Dis 1996; 7:529-534
26. Chen MC, Chang HW, Wu CJ, et al. Percutaneous transluminal mitral valvuloplasty reduces circulating soluble CD40 ligand in rheumatic mitral stenosis. Chest 2005; 128:36-41
27. Aggarwal A, Schneider DJ, Terrien EF, et al. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 2004; 93:6-9
28. Tsakiris DA, Tschopl M, Wolf F, et al. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2000; 11:165-173
29. Brueckmann M, Bertsch T, Lang S, et al. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med 2004; 42: 1132-1139
30. Danese S, Scaldaferri F, Papa A, et al. CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. Arterioscler Thromb Vasc Biol 2004; 24:e162
31. Mant MJ, Kappagoda CT, Taylor RF, et al. Transcoronary platelet activation and consumption in coronary artery disease: studies at rest. Thromb Res 1988; 50:201-211
32. Stine RA, Magorien RD, Bush CA, et al. Failure of percutaneous transluminal coronary angioplasty to stimulate platelet and prostaglandin activity. Cathet Cardiovasc Diagn 1985; 11:247-254
33. Thanyasiri P, Celermajer DS, Adams MR. Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease. Am J Physiol Heart Circ Physiol 2005; 289:513-517
34. Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004; 110:1916-1919
35. Jaremo P, Lindahl TL, Fransson SG, et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252:233-238
36. Doi N, Nishio K, Nakatani H, et al. Decreased plasma soluble P-selectin level in coronary sinus after successful coronary angioplasty in patients with unstable angina. J Cardiol 1999; 33:251-256
37. Inoue T, Hoshi K, Yaguchi I, et al. Serum levels of circulating adhesion molecules after coronary angioplasty. Cardiology 1999; 91:236-242
38. Salgado Filho W, Martinez Filho EE, et al. Intracoronary inflammatory markers after percutaneous coronary interventions. Ar Qbras Cardiol 2005; 85:180-185
39. Mulvihill NT, Foley JB, Walsh MA, et al. Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules. Int J Cardiol 2001; 77:223-229
40. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002; 143:118-123
41. Tomai F, Ghini AS, Ferri C, et al. Effects of carbon-coated coronary stents on the markers of inflammation, thrombin generation and platelet and endothelial activation. Ital Heart J 2003; 4:23-28
42. Aggarwal A, Blum A, Schneider DJ, et al. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 2004; 15:471-475
43. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108:2776-2782
44. Vavuranakis M, Latsios G, Aggelis D, et al. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels. Clin Ther 2006; 28:860-871
45. Jaumdally RJ, Varma C, MacFadyen RJ, et al. Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in patients with coronary artery disease. J Thromb Thrombolysis 2007; 23:189-194